Maze Therapeutics is a clinical-stage biopharmaceutical company that uses human genetics to design small-molecule precision medicines. Its approach aims to mimic protective genetic variants that naturally reduce disease risk or progression. The pipeline targets common diseases, guided by the company’s Maze Compass genetics platform.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -33.7 | — |
| Q3 2025 | 0 | — | -30.1 | — |
| Q4 2025 | 0 | — | -34.6 | — |
| Q1 2026 | 20 | — | -24.2 | — |
| Q2 2026 | 0 | — | -44.7 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Safety Insurance Group, Inc. (SAFT), Pathward Financial, Inc. (CASH), Immunocore Holdings plc (IMCR), Target Hospitality Corp. (TH), uniQure N.V. (QURE), Ocular Therapeutix, Inc. (OCUL)